Visiox Pharma Inc. announced it has entered into a definitive agreement with Santen Pharmaceutical Co., Ltd. to license OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, a New Chemical Entity (NCE) recently approved by the U.S. Food and Drug Administration (FDA). OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Visiox plans to launch OMLONTI in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%, positioning the company to become a leader in glaucoma, a disease with significant impact on patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,529 JPY | +0.39% | +1.09% | +8.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.83% | 3.62B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Visiox Pharma Enters into A Definitive Agreement with Santen Pharmaceutical Co., Ltd to License OMLONTI